期刊文献+

血清HE4和CA125在卵巢上皮癌中的诊断价值 被引量:6

The value of serum HE4 and CA125 tests in the diagnosis of epithelial ovarian cancer
下载PDF
导出
摘要 目的通过盆腔包块患者血清HE4和CA125的检测来评估盆腔包块患者患卵巢上皮癌风险,以探讨血清HE4和CA125在卵巢上皮癌中的诊断价值。方法用CMIA法检测2013年5月-2015年7月在我院妇科住院并手术的244例盆腔包块患者的血清HE4水平及CA125水平,进行统计比较。同时根据患者绝经情况通过公式计算出患卵巢癌的风险度(ROMA)。结果 HE4在33例卵巢上皮癌中29例高度表达;而其他177例盆腔包块患者中只有3例高度表达;在其他妇科恶性肿瘤中34例只有一例高表达。CA125除在33例卵巢上皮癌中31例高度表达外,在卵巢子宫内膜异位囊肿,盆腔炎性包块(尤其急性炎性包块)中均有约60%以上高度表达。在33例卵巢上皮癌中通过ROMA值将30例分到了高危组,检出率为90.91%。良性肿瘤177例,分到高危组9例,假阳性率为5.08%;其他妇科恶性肿瘤34例中只有一例分到高危组。结论血清HE4和CA125在卵巢上皮癌的诊断中具有重要价值。 Objective To explore the value of serum HE4 and CA125 tests in the diagnosis of epithelial ovarian cancer through the risk evaluation of epithelial ovarian cancer based on serum HE4 and CA125 tests in the patients with pelvic masses. Methods By the CMIA tests, the serum HE4 and CA125 levels of 244 patients with pelvic masses who received surgeries in our hospital from May 2013 to July 2015 were recorded and compared. The ovarian cancer risk of the patients was calculated by formula(ROMA) according to their menopausal status. Results There were 29 cases with positive expressions of HE4 among 33 patients with epithelial ovarian cancers. There were 3 cases with positive expressions of HE4 among 177 patients with pelvic masses. And there were only 1 case with positive expression of HE4 among 34 cases with other gynecological malignant tumors. There were 31 cases with positive expressions of CA125 among 33 patients with epithelial ovarian cancers, while in the patients with ovarian endometrial implantation cysts or pelvic inflammatory masses(especially acute inflammatory masses), the cases with positive expressions of CA125 account for more than 60% of total. According to the ROMA values, 30 cases of the patients with epithelial ovarian cancer were assigned to the high risk group, the positive rate was 90.91%, 9 cases of the patients with benign tumors were assigned to the high risk group, the false positive rate was 5.08%. Only 1 case of the 34 patients with other gynecological malignant tumors was assigned to the high risk group. Conclusion The serum HE4 and CA125 tests are very important in the diagnosis of epithelial ovarian cancer.
出处 《中国医药科学》 2016年第7期169-171,174,共4页 China Medicine And Pharmacy
基金 广东省东莞市科技计划医疗卫生类科研项目(201110515000204)
关键词 人附睾蛋白4(HE4) CA125 ROMA 卵巢癌 盆腔包块 Human epididymis protein 4(HE4) CA125 Risk ovarian malignancy algorithm(ROMA) Ovarian cancer Pelvic mass
  • 相关文献

参考文献19

  • 1Oberaigner W,Minicozzi p,Bieiska-Lasota M,et al.Survival for ovarian Cancer in Europe:the across-country variation did not shrink in the past decade[J].Acta oncol,2012,51(4):441-453.
  • 2Anastasi E,Granato T,Coppa A,et al.HE4 in the differential diagnosis of a pelvic mass:a case report[J].Int JMol Sci,2011,12(1):627-632.
  • 3Hellstrom l,Raycraft J,Hayden-ledbetter M,et al.The HE4(Wfd C2)protein is abiomarker for ovarian carcinoma[J].Cancer Res,2003,63(3):695-700.
  • 4Moore Rg,Mc Meekin Ds,Brown Ak,et al.A novel multiple marker bioassay utillizing HE4 and CA125 for the prediction of ovarian cancer in patients with apelvic mass[J].Gynecol Oncol,2009,11(2):40-46.
  • 5Moore RG,Brown AK,Miller MC,et al.The use of multiple novel tumor biomarker for the detection of ovarian carcinoma in patients with a pelvic mass[J].Gynecol Oncol,2008,10(8):402-408.
  • 6Cristina A,Filomena MC,Elci IO,et al.A comparison of CA125,HE4,risk ovarian malignancy algorithm(ROMA)and risk malignancy index(RMI)for the classification of ovarian masses[J].Clinics,2012,67(5):437-441.
  • 7Karolina P,Bjorg KJ,Karin S,et al.Evaluation of ovarian cancer biomarkers HE4 and CA125 women presenting with a suspicios cystic ovarian masses[J].Gynecol Oncol,2012,22(4):244-252.
  • 8杨彩虹,张雪玉.人附睾蛋白4在妇科恶性肿瘤中的研究进展[J].医学综述,2010,16(20):3081-3083. 被引量:9
  • 9孙桂荣,丛培珊.卵巢癌、子宫内膜癌肿瘤标志物人附睾蛋白4[J].中国医刊,2010,45(11):86-88. 被引量:8
  • 10郑丽娥,曲军英,李桑,苏玉红.人附睾蛋白4在卵巢恶性肿瘤早期诊断中的作用[J].中国临床药理学杂志,2014,30(11):996-999. 被引量:7

二级参考文献86

  • 1戴晴,刘真真,姜玉新,杨佳欣,吕珂,冷金花,高嫔.经阴道超声造影在附件包块诊断中的应用研究[J].中华超声影像学杂志,2006,15(9):693-697. 被引量:37
  • 2[1]Vlasova MA,Moshkovskii SA,Safarova MP,et al.Molecular di-agnostics of ovarian cancer using proteome techniques[J].Bi-omed Khim,2005,51(4):367-383.
  • 3[2]Leen E,Moug SJ,Horgan P.Potential impact and utilization of ultrasound contrast media[j].Eur Radiol,2004,14(Supple8):16-24.
  • 4[3]Leen E.The role of contrast-enhanced ultrasound in the char-acterization of focal liver lesion[J].Eur Razdiol,2001.11(Supple 3):E27-34.
  • 5[4]Harvey,CJ,Pilcher JM,Eckersley RJ,et al.Advances in Ultra-sound[J].Clin Radiol,2002,57(3):157-177.
  • 6[5]Immer FF,Seiler AM,Aeschbacher BC,et al.Influence of the ultrasound contrast agent Levovist on human nailfold capillary mi-crocirculation[J].Angiology,2000,51(2):193-199.
  • 7[6]Less JR,Skalak TC,Sevick EM,et al.Microvascular archi-tecturc in a mammary carcinoma:branching patterns and vessel dimensions[J].Cancer Res,1991,51(1):265-273.
  • 8[7]D'Arey T J,Jayaram V,Lynch M,et al Ovarian cancel-de-tected non-invasively by contrast enhanced power Doppler ultra-sound[J].Br Obstet Gynecol,2004,111(6):619-622.
  • 9[9]Testa AC,Ferrandina G.Fruscella E,et al The use of con-trasted transvaginal sonography in the diagnosis of gynecologic diseases:a preliminary study[J].J Ultrasound Med,2005,24(9):1267-1278.
  • 10[10]Kohzuki M,Kanzaki T,Murata Y.Contrast-enhanced power Doppler sonography of malignant ovarian tumors using harmonic flash-echo imaging:Preliminary experience[J].Clin Ultra-sound,2005,33(5):237-242.

共引文献927

同被引文献62

引证文献6

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部